Midostaurin: FLT3 Inhibitor for AML & Systemic Mastocytosis
Midostaurin is a highly effective, oral multi-targeted kinase inhibitor. It specifically targets and blocks the activity of multiple enzymes, most notably the mutated FLT3 and KIT tyrosine kinases, which drive the abnormal proliferation of cancer cells.
By disrupting these signaling pathways, Midostaurin induces apoptosis (cell death) in leukemic cells. It represents a major breakthrough in hematology, significantly improving overall survival rates when combined with standard chemotherapy in specific genetic subtypes of leukemia.
Additionally, it is a cornerstone therapy for advanced forms of systemic mastocytosis, a rare disorder where mast cells accumulate in internal organs, largely driven by the KIT D816V mutation.
Indications
- Acute Myeloid Leukemia (AML): Indicated for the treatment of newly diagnosed AML in adults who are FLT3 mutation-positive, in combination with standard cytarabine and daunorubicin/idarubicin induction and cytarabine consolidation.
- Systemic Mastocytosis: Treatment of adult patients with Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN), or Mast Cell Leukemia (MCL).
Dosage and administration
Midostaurin is supplied as 25 mg soft capsules. Dosage varies based on the indication:
- For AML: 50 mg (two 25 mg capsules) orally twice daily on days 8 to 21 of each cycle of induction and consolidation chemotherapy.
- For Systemic Mastocytosis: 100 mg (four 25 mg capsules) orally twice daily (every 12 hours).
- Administration: Take with food to reduce nausea and optimize absorption. Swallow capsules whole with a glass of water; do not open, crush, or chew.
Midostaurin is supplied as 25 mg soft capsules. Dosage varies based on the indication:
- For AML: 50 mg (two 25 mg capsules) orally twice daily on days 8 to 21 of each cycle of induction and consolidation chemotherapy.
- For Systemic Mastocytosis: 100 mg (four 25 mg capsules) orally twice daily (every 12 hours).
- Administration: Take with food to reduce nausea and optimize absorption. Swallow capsules whole with a glass of water; do not open, crush, or chew.
Patients must be closely monitored during therapy. Common and severe side effects include:
- Hematologic: Febrile neutropenia (fever with low white blood cells), increased risk of infections, and bleeding events (petechiae, epistaxis).
- Gastrointestinal: Nausea and vomiting (prophylactic antiemetics are strongly recommended), diarrhea, stomatitis.
- Cardiopulmonary: Prolongation of the QT interval on ECG, pulmonary toxicity (interstitial lung disease, pneumonitis).
- General: Headache, musculoskeletal pain.
